Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

928 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model.
Beckwith KA, Frissora FW, Stefanovski MR, Towns WH, Cheney C, Mo X, Deckert J, Croce CM, Flynn JM, Andritsos LA, Jones JA, Maddocks KJ, Lozanski G, Byrd JC, Muthusamy N. Beckwith KA, et al. Among authors: jones ja. Leukemia. 2014 Jul;28(7):1501-10. doi: 10.1038/leu.2014.32. Epub 2014 Jan 21. Leukemia. 2014. PMID: 24445867 Free PMC article.
Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia.
Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, Johnson AJ, Smith LL, Zhao Y, Ling Y, Li J, Phelps MA, Grever MR, Byrd JC, Flynn JM. Stephens DM, et al. Leuk Res. 2013 Oct;37(10):1195-9. doi: 10.1016/j.leukres.2013.06.006. Epub 2013 Jul 15. Leuk Res. 2013. PMID: 23867058 Free PMC article. Clinical Trial.
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R, Setter B, Jones J, Flynn JM, Andritsos L, Devine S, Mo X, Jarjoura D, Tridandapani S, Algate P, Byrd JC, Muthusamy N. Rafiq S, et al. MAbs. 2013 Sep-Oct;5(5):723-35. doi: 10.4161/mabs.25282. Epub 2013 Jun 7. MAbs. 2013. PMID: 23883821 Free PMC article.
Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients.
Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC. Stephens DM, et al. Among authors: jones ja. Am J Hematol. 2015 Nov;90(11):967-9. doi: 10.1002/ajh.24125. Epub 2015 Oct 12. Am J Hematol. 2015. PMID: 26202978 Free PMC article.
Tumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B-cell cytotoxicity in chronic lymphocytic leukemia.
Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, Rader C, Phelps MA, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N. Mani R, et al. Leukemia. 2015 Feb;29(2):346-55. doi: 10.1038/leu.2014.199. Epub 2014 Jun 20. Leukemia. 2015. PMID: 24947019 Free PMC article.
928 results